Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

gallium Ga 68-NeoB

A radioconjugate consisting of a gastrin-releasing peptide receptor (GRPR) antagonist linked via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope gallium Ga 68, with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration, gallium Ga 68-NeoB binds to GRPRs present on cancer cells. Upon binding, this radioconjugate can be used to quantify tumor uptake of NeoBOMB1 using PET/CT. GRPR, also known as bombesin receptor subtype 2, is a G protein-coupled receptor that is overexpressed in some cancer types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[68Ga]-NeoB
68Ga-DOTA-NeoBOMB1
68Ga-NeoB
gallium Ga 68 NeoBOMB1
gallium-68 DOTA-NeoBOMB1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search